<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During an 8-year period, 28 young adults (median age 27 years) and 30 children (median age 10 years) with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> have received allogeneic bone marrow transplantation (BMT) from major histocompatibility locimatched sibling donors after preparation with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and total lymphoid irradiation (TLI) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> recipients were previously transfused </plain></SENT>
<SENT sid="2" pm="."><plain>Comparison of post-bone marrow transplantation events in adults and children reveals equivalent median time to engraftment, median duration of hospitalization, median Karnofsky assessment of activity, and equivalent low rejection rate </plain></SENT>
<SENT sid="3" pm="."><plain>Although the incidence of moderate and severe <z:hpo ids='HP_0011009'>acute</z:hpo> graft-v-host disease (GVHD) and of extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was greater in adults than in children, the projected survival at 4 years of adults (67%; 95% confidence interval [CI] 49% to 85%) and of children (73%; 95% CI 57% to 89%) was equivalent </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> survivors are transfusion-free and have <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood counts </plain></SENT>
<SENT sid="5" pm="."><plain>One of 28 adults and 2 of 30 children have experienced rejection, and 1 of these patients survives after a second transplant </plain></SENT>
<SENT sid="6" pm="."><plain>No <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> have been identified following transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>An unexpectedly high incidence of <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> has been detected and may be attributable to preparation of recipients with TLI </plain></SENT>
<SENT sid="8" pm="."><plain>Therapy of severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> with allogeneic BMT after preparation with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and TLI offers a high rate of transfusion-free survival and a low rejection rate in previously transfused young adults and children </plain></SENT>
</text></document>